Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lineage Therap (LCTX – Research Report), Axonics Modulation Technologies (AXNX – Research Report) and Artivion (AORT – Research Report).
Lineage Therap (LCTX)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lineage Therap today and set a price target of $7.00. The company’s shares closed last Friday at $1.06.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lineage Therap with a $5.25 average price target.
See the top stocks recommended by analysts >>
Axonics Modulation Technologies (AXNX)
In a report released today, Michael Matson from Needham maintained a Hold rating on Axonics Modulation Technologies. The company’s shares closed last Friday at $67.28, close to its 52-week high of $69.68.
According to TipRanks.com, Matson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Axonics Modulation Technologies is a Hold with an average price target of $71.00, representing a 5.4% upside. In a report issued on April 23, Wells Fargo also maintained a Hold rating on the stock with a $71.00 price target.
Artivion (AORT)
In a report released today, Frank Takkinen from Lake Street maintained a Buy rating on Artivion, with a price target of $28.00. The company’s shares closed last Friday at $20.93, close to its 52-week high of $21.90.
According to TipRanks.com, Takkinen is a 2-star analyst with an average return of
Artivion has an analyst consensus of Strong Buy, with a price target consensus of $25.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LCTX:
